The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Mycophenolate Mofetil Decreases Acute Rejection and may Improve Graft Survival in Renal Transplant Recipients When Compared with Azathioprine: A Systematic Review
Abstract
BACKGROUND: Mycophenolate mofetil (MMF) has increasingly replaced azathioprine (AZA) as the antimetabolite of choice in immunosuppressive protocols. Initial trials comparing MMF with AZA in patients receiving cyclosporine A sandimmune showed a clinical benefit in reducing the incidence of acute rejections. It has been questioned whether this benefit remains significant when using newer formulations of cyclosporine A (neoral) and tacrolimus. METHODS: Literature searches were performed using the Transplant Library, Cochrane library, Medline, and Embase for all randomized controlled trials directly comparing MMF with AZA in renal transplant recipients. Trials were assessed for quality using the Jadad scoring system. Trials were pooled using meta-analysis software. Confidence intervals were set at 95%. RESULTS: Nineteen relevant studies were identified, including a total of 3143 patients. MMF significantly reduces the risk of acute rejection when used in combination with any calcineurin inhibitor (relative risk 0.62, 0.55-0.87, P<0.00001). The hazard for graft loss, including death with a functioning graft, is also significantly reduced in patients treated with MMF (hazard ratio 0.76, 0.59-0.98, P=0.037). There is no significant difference in patient survival or renal transplant function between groups. Risk of adverse events, including cytomegalovirus infection, anemia, leukopenia or rates of malignancy, does not differ significantly. A greater risk of diarrhea is seen in MMF-treated patients. CONCLUSIONS: We have shown that MMF used with a calcineurin inhibitor does indeed confer a clinical benefit over AZA by reducing the risk of acute rejection and also possibly reducing graft loss. This effect is independent of whether MMF is used in combination with sandimmune, neoral or tacrolimus.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Imputing missing standard deviations in meta-analyses can provide accurate results
Furukawa, T. A., Barbui, C., Cipriani, A., Brambilla, P., & Watanabe, N. (2006) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2005.06.006 · Cited by 1,568 · cited 1×
“Otherwise, a pooled standard deviation was calculated for all similar studies in the current meta-analysis and applied to studies with missing values (15).”
Method
Cited by
Special Issue: KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients
Eckardt, K.-U., Kasiske, B. L., & Zeier, M. G. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.02834.x · Cited by 1,499
Debout, A., Foucher, Y., Trébern-Launay, K., Legendre, C., Kreis, H., Mourad, G., Garrigue, V., Morelon, E., Buron, F., Rostaing, L., et al. (2015) · Kidney International · doi:10.1038/ki.2014.304 · Cited by 410
Diagnosis and prevention of chronic kidney allograft loss
Nankivell, B. J., & Kuypers, D. R. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60699-5 · Cited by 324
Nelson, J., Alvey, N., Bowman, L., Schulte, J., Segovia, M. C., McDermott, J., Te, H. S., Kapila, N., Levine, D. J., Gottlieb, R. L., et al. (2022) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2716 · Cited by 130
Neofytos, D., Chatzis, O., Nasioudis, D., Boely Janke, E., Doco Lecompte, T., Garzoni, C., Berger, C., Cussini, A., Boggian, K., Khanna, N., et al. (2018) · Transplant Infectious Disease · doi:10.1111/tid.12898 · Cited by 108
Metadata
- Authors
- Knight, S. R., Russell, N. K., Barcena, L., & Morris, P. J.
- Venue
- Transplantation
- Published
- 2009-03-27
- Volume
- 87
- Issue
- 6
- Pages
- 785-794
- ISSN
- 0041-1337 (ISSN-L)
- OpenAlex
- W2056316390
- Cited by
- 179
- References
- 1
- FWCI
- 2.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mycophenolate Mofetil Decreases Acute Rejection and may Improve Graft Survival in Renal Transplant Recipients When Compared with Azathioprine: A Systematic Review. https://app.cochat.ai/papers/10.1097/tp.0b013e3181952623
- The paper
- Knight, S. R., Russell, N. K., Barcena, L., & Morris, P. J. (2009). Mycophenolate Mofetil Decreases Acute Rejection and may Improve Graft Survival in Renal Transplant Recipients When Compared with Azathioprine: A Systematic Review. Transplantation. https://doi.org/10.1097/tp.0b013e3181952623
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.